Which skin disease affects more than 70 million people worldwide, is not life-threatening yet has a lasting impact on patients and very limited treatment options, and once affected even the King of Pop, Michael Jackson? With vitiligo still carrying a high level of unmet medical need, the Aphrodite Group, together with Elixiron, Happy Recome and YIRI Aesthetics, held a public-interest event on April 24 titled “Beyond Vitiligo: A Screening and Conversation,” with patients invited to attend.
The event combined a screening of the Michael Jackson biographical film with a panel discussion among experts from several fields, focusing on scientific progress in the disease, the limitations of current therapies, and future treatment directions.
You Are Not Alone: Building Social Support and Policy Backing
Lin Shih-Chia, Chief Executive Officer of the Foundation of Medical Professionals Alliance in Taiwan, noted during the discussion that vitiligo has long been an underestimated and overlooked disease. Its impact on patients goes well beyond patches of altered skin color, extending to self-identity and social life. Echoing the Michael Jackson classic “You Are Not Alone,” she said: “Patients are not alone. We should work together to promote the integration of medical resources across specialties and policy support, and to build accurate public understanding of vitiligo.”
Beyond the disease itself, the psychological injury and the social difficulties it brings are what we need to understand and overcome, so that patients receive better psychological care and improved access to treatment.
I’ll Be There: Support from the Medical System, Encouraging Patients to Face the Disease
Dr. Chen Yu-Tsung, Director of the Aphrodite Silk Hair Restoration Clinic and Deputy Director of the Aphrodite Skin Clinic, drew on another well-known song, “I’ll Be There,” to encourage patients not to give up in the face of current setbacks, and to consider the range of available treatments alongside camouflage options. He said directly: “Current first-line options, including topical agents, narrowband UVB phototherapy and autologous cell transplantation, still have real limits in repigmentation speed, variable results across body sites, and the time required. That is precisely why frontline physicians and patients are so eager for a next-generation drug with the potential for durable remission.” He expressed confidence that medical teams will help patients find the most suitable option among existing resources, while looking forward to a breakthrough from precision medicine.
A Precision Immunology Breakthrough: Taiwanese Antibody Drug Development on the World Stage
Dr. Cheng-Lung Ku, Chief Scientific Officer of Elixiron, shared key mechanistic findings in vitiligo. He explained that interferon-gamma (IFN-γ) is the critical driver of disease onset, activating signaling pathways and forming a self-amplifying inflammatory loop.
Dr. Tseng Wen-Shang, President of Aphrodite Medical Group
Ms. Chen Hui-Ying, Chairperson of Happy Recome and Chair of the Happy Care Foundation
Through a shared screening of the Michael Jackson biographical film and an exchange among experts from several fields, the event focused on scientific progress in the disease, the limitations of current therapies, and future treatment directions. Speakers, from left: Ms. Lin Shih-Chia, CEO of the Foundation of Medical Professionals Alliance in Taiwan and General Manager of Tai-An Biotechnology; Dr. Chen Yu-Tsung, Deputy Director of the Aphrodite Skin Clinic; and Dr. Cheng-Lung Ku, Chief Scientific Officer of Elixiron. Photo courtesy of GeneOnline.
Elixiron is one of very few pioneers in Taiwan working in vitiligo, and currently holds the only large-molecule antibody drug under development for this disease in the country. It has become one of the most competitive and leading antibody-targeting programs in this field worldwide. “Vitiligo is a local amplification of specific inflammatory signals rather than a systemic loss of immune control,” Dr. Ku explained, noting that the treatment trend is moving from broad immunosuppression toward precision modulation.
The anti-interferon-gamma monoclonal antibody developed by Elixiron is designed to reduce downstream autoimmune damage at its source. This differs from the pathway taken by existing small molecule inhibitors, and the aim is to address patient needs with greater precision and improved safety.
Heal the World: Patient-Centered Care and a Vision for the Future
Closing the panel, Dr. Ku said: “Michael Jackson’s ‘Heal the World’ expresses the future we share.”Beyond healing patches on the skin through scientific innovation, the psychological injury the disease brings also needs to be addressed. “Vitiligo treatment is entering a new chapter. We believe that combining scientific innovation with social engagement can build a future for patients that is more supportive and less constrained.” This screening and panel served as more than a medical and scientific exchange. It stood as evidence of a shared commitment between the medical community and the patient community.
Related coverage:
- United Daily News: https://udn.com/news/story/7241/9464625
- Yam News: https://n.yam.com/Article/20260427989839
- Commercial Times: https://www.ctee.com.tw/news/20260429701331-431205
- Economic Daily News: https://money.udn.com/money/story/123828/9470502
- The News Lens: https://www.thenewslens.com/article/267119
- LEHO: https://leho.com.tw/archives/294632
- My Housing: https://www.myhousing.com.tw/l/l04/271967/
- PChome News: https://news.pchome.com.tw/society/firenews/20260429/index-77743143186379341002.html
- Insight News Network: https://insightnews.network/archives/122995
- Top1Health: https://www.top1health.com/article/97958
